VIRX Viracta Therapeutics: Bozor kapitallashuvining balans qiymatiga nisbati

viracta.com (VIRX) - korporativ logo

Viracta Therapeutics (VIRX) kompaniyasining kitob qiymatiga nisbatan narx koeffitsiyenti limfomalar bilan kurashish uchun aniq usullarni ishlab chiquvchi brendning moliyaviy barqarorligini namoyish etadi. Bu yerda yetakchi onkologlar jamoasi ilg'or epigenetik texnologiyalarni rivojlantirmoqda. Biroq, klinik sinovlarga ishtirokchilarning sekin jalb qilinishi va likvidlik tanqisligi bosim yaratmoqda, 0.25 esa emitentning xavfsizlik zaxirasini belgilovchi joriy metrika darajasi vazifasini o'tamoqda.

Viracta Therapeutics, Inc. (VIRX) - Bozor kapitallashuvining balans qiymatiga nisbati 04.07.2022dan 16.02.2025gacha

VIRX (Viracta Therapeutics): tahliliy kesimlar va indikatorlar boʻyicha maʼlumotlar

- narx va narxlar bo'yicha konsensus prognoz:
Aksiya kotirovkalari viracta.com|VIRX - Investitsiya uylarining umumiy prognozi
- bozor kapitallashuvi bo'yicha ma'lumotlar:
Bozor kapitallashuvi Viracta|VIRX - Kompaniyani butunlay sotib olishdagi haqiqiy narx
- balans kapitallashuvi bo'yicha ma'lumotlar:
Bitta aksiya hisobiga balans qiymati Viracta Therapeutics|VIRX - Balans kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati viracta.com|VIRX - Biznesning umumiy aktivlari
- qarz va likvidlik bo'yicha ma'lumotlar:
Umumiy qarzning kapitalga nisbati Viracta Therapeutics|VIRX - Uzoq muddatli qarzning o'z kapitaliga nisbati|Qisqa muddatli qarzning kapitalga nisbati viracta.com|VIRX - Kompaniyaning umumiy yig'indi qarzi|Qarzning balans kapitallashuviga nisbati Viracta|VIRX - Kompaniyaning uzoq muddatli kredit va qarzlari|Kompaniyaning qisqa muddatli majburiyatlari Viracta Therapeutics
Fundamental baholash:VIRX (Viracta Therapeutics Inc.)
Viracta Therapeutics tayyor mahsulotlari

Ushbu koeffitsient aksiyalarning bozor qiymatini kompaniyaning sof aktivlari bilan solishtirib, bozor kapitalni kitob qiymatiga nisbatan qanchalik hadda ortiq baholashini aniqlaydi. Joriydagi narxning kitob qiymatiga nisbati (price-to-book) multiplikatori tendentsiyasini tahlil qilish orqali investor narx korreksiyasi xavfini baholaydi. Viracta Therapeutics (VIRX) uchun ushbu ko'rsatkich Epstein-Barr virusini faollashtirishni nazarda tutuvchi noyob onkologiya strategiyasiga bo'lgan bozor kutuvlarini aks ettiradi. Bu yerdagi yuqori qiymatlar kelajakdagi tibbiy muvaffaqiyatga tikilgan garovdan dalolat beradi.

Asosiy raqobatchilar

Kapitallashuvning sof aktivlarga nisbati BeiGene Ltd|halozyme.com (HALO) - Kapitallashuvning balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati RVMD|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma Group International|Bozor kapitallashuvining balans qiymatiga nisbati CGON|Bozor kapitallashuvining balans qiymatiga nisbati URGN (UroGen Pharma Corp)|BCAX - Bozor qiymatining balans qiymatiga nisbati|Kapitallashuvning balans qiymatiga nisbati personalis.com PSNL|ERAS: Bozor kapitallashuvining balans qiymatiga nisbati|DCTH - Kapitallashuvning sof aktivlarga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati YMAB|AURA (Aura Corp) - Bozor qiymatining balans qiymatiga koeffitsiyenti|CADL - Bozor qiymatining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati accuray.com (ARAY)|SELLAS Life Sciences (SLS) - Kapitallashuvning sof aktivlarga nisbati|Balans qiymatiga nisbatan bozor qiymati Actuate Therapeutics Inc. (ACTU)|Citius Oncology, Inc - Bozor kapitallashuvining balans qiymatiga nisbati|HURA - Kapitallashuvning sof aktivlarga nisbati|Protara Therapeutics - Kapitallashuvning sof aktivlarga nisbati|FATE: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati aadibio.com WHWK|TScan Therapeutics, Inc. (TCRX) - Balans qiymatiga nisbatan bozor qiymati|Bozor kapitallashuvining balans qiymatiga nisbati CSBR (Champions Oncology Inc)|Bozor qiymatining balans qiymatiga koeffitsiyenti XBiotech USA (XBIT)|Kapitallashuvning sof aktivlarga nisbati CEL-SCI Corporation (CVM)|Bozor qiymatining balans qiymatiga nisbati ostherapies.com (OSTX)|Bozor kapitallashuvining balans qiymatiga nisbati RADX|Artiva Biotherapeutics Inc. - Balans qiymatiga nisbatan bozor kapitallashuvi|Bozor qiymatining balans qiymatiga nisbati Adlai Nortye Limited (ANL)|VERU - Balans qiymatiga nisbatan bozor qiymati|TPST: Bozor kapitallashuvining balans qiymatiga nisbati|Xilio Therapeutics (XLO) - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor kapitallashuvining balans qiymatiga nisbati RENB|Kapitallashuvning sof aktivlarga nisbati Mural Bio (MURA)|Kapitallashuvning sof aktivlarga nisbati Kairos Pharma Ltd|Bozor kapitallashuvining balans qiymatiga multiplikatori onkuretherapeutics.com (OKUR)|Bozor kapitallashuvining balans qiymatiga nisbati GDTC (CytoMed Therapeutics Limited)|CRIS - Bozor kapitallashuvining balans qiymatiga nisbati|Kapitallashuvning sof aktivlarga nisbati Apollomics Corp (APLM)|Tharimmune Inc (THAR) - Balans qiymatiga nisbatan bozor qiymati|ADVB - Kapitallashuvning sof aktivlarga nisbati|Genprex Inc (GNPX) - Bozor kapitallashuvining balans qiymatiga multiplikatori|CLDI - Bozor kapitallashuvining balans qiymatiga nisbati|Balans qiymatiga nisbatan bozor qiymati sunshinebiopharma.com|Xenetic Biosciences - Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga koeffitsiyenti SLRX (Salarius Pharmaceuticals Inc)|Bozor qiymatining balans qiymatiga nisbati Purple Biotech Corp|Balans qiymatiga nisbatan bozor qiymati American Oncology Network Inc AONC|BeiGene, Ltd. - Bozor kapitallashuvining balans qiymatiga nisbati|CKPT: Bozor kapitallashuvining balans qiymatiga nisbati|Bozor qiymatining balans qiymatiga nisbati Elevation Oncology (ELEV)|iCAD (ICAD) - Sof aktivlarga nisbatan bozor kapitallashuvi|Bozor kapitallashuvining balans qiymatiga nisbati IKNA (Ikena Oncology Inc.)|Bozor qiymatining balans qiymatiga koeffitsiyenti Notable Labs Corp (NTBL)|Kapitallashuvning sof aktivlarga nisbati MOR|Bozor kapitallashuvining balans qiymatiga nisbati nayabiosciences.com NAYA|Kapitallashuvning sof aktivlarga nisbati Ascentage Pharma (AAPGV)